Signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins
View Patent ↗Polypeptide signal sequences of modified fragments of human immunoglobulin heavy chain binding protein (Bip) are disclosed. Also disclosed are fusion proteins comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip) operably linked to a heterologous polypeptide. Also disclosed are protein expression vectors comprising a promoter operably linked to a first DNA sequence encoding a signal sequence comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip) and a second DNA sequence encoding a heterologous polypeptide fused in frame to the first DNA sequence. Further disclosed are methods of producing a polypeptide comprising expressing a fusion protein comprising a polypeptide signal sequences of modified fragments of human immunoglobulin heavy chain binding protein (Bip) operably linked to a heterologous polypeptide and recovering the heterologous polypeptide.
1. A signal polypeptide comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip), wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) has the amino acid sequence of SEQ ID NO: 19 with an insertion of seven to ten amino acid residues after position 13 of SEQ ID NO: 19, and wherein the last four inserted amino acid residues are leucine residues, and wherein the signal polypeptide is effective for a protein translocation when fused to the protein.
2. The signal polypeptide of claim 1 wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) has the amino acid sequence of SEQ ID NO: 20.
3. The signal polypeptide of claim 1 wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) has the amino acid sequence of SEQ ID NO: 21.
4. The signal polypeptide of claim 1 wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) has the amino acid sequence of SEQ ID NO: 22.
5. The signal polypeptide of claim 1 wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) has the amino acid sequence of SEQ ID NO: 23.
6. A fusion protein comprising the signal polypeptide of claim 1 operably linked to a heterologous polypeptide.
7. The fusion protein of claim 6 wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) polypeptide signal sequence has amino acid sequence of SEQ ID NO: 20.
8. The fusion protein of claim 6 wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) polypeptide signal sequence has the amino acid sequence of SEQ ID NO: 21.
9. The fusion protein of claim 6 wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) polypeptide signal sequence has the amino acid sequence of SEQ ID NO: 22.
10. The fusion protein of claim 6 wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) polypeptide signal sequence has the amino acid sequence of SEQ ID NO: 23.
11. The fusion protein of claim 6 wherein the heterologous polypeptide comprises one or more enzymes, one or more biological response modifiers, one or more toxins, one or more antibodies, one or more fragments of the heterologous polypeptide, or any combination thereof.
12. The fusion protein of claim 6 wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) polypeptide signal sequence has the amino acid sequence of SEQ ID NO: 20 and the heterologous polypeptide comprises one or more of the following: acid β-glucocerebrosidase, acid α-galactosidase, acid α-glucosidase, proinsulin, insulin-like growth hormone-2 (IGF-2), interferon, therapeutic antibody and an insulin-like growth hormone-1 (IGF-1).
13. The fusion protein of claim 6 wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) polypeptide signal sequence has the amino acid sequence of SEQ ID NO: 21 and the heterologous polypeptide comprises one or more of the following: acid β-glucocerebrosidase, acid α-galactosidase, acid α-glucosidase, proinsulin, insulin-like growth hormone-2 (IGF-2), interferon, therapeutic antibody or an insulin-like growth hormone-1 (IGF-1).
14. The fusion protein of claim 6 wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) polypeptide signal sequence has the amino acid sequence of SEQ ID NO: 22 and the heterologous polypeptide comprises one or more of the following: acid β-glucocerebrosidase, acid α-galactosidase, acid α-glucosidase, proinsulin, insulin-like growth hormone-2 (IGF-2), interferon, therapeutic antibody or an insulin-like growth hormone-1 (IGF-1).
15. The fusion protein of claim 6 wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) polypeptide signal sequence has the amino acid sequence of SEQ ID NO: 23 and the heterologous polypeptide comprises one or more of the following: acid β-glucocerebrosidase, acid α-galactosidase, acid α-glucosidase, proinsulin, insulin-like growth hormone-2 (IGF-2), interferon, therapeutic antibody or an insulin-like growth hormone-1 (IGF-1).
16. A method of producing a polypeptide, comprising:
(a) expressing a fusion protein comprising the signal polypeptide of claim 1 operably linked to a heterologous polypeptide; and
(b) recovering said heterologous polypeptide.
17. A method of increasing protein expression, comprising:
(a) expressing a fusion protein comprising the signal polypeptide of claim 1 and a heterologous protein, and
(b) recovering the heterologous protein.
18. A method of increasing protein secretion, comprising:
(a) expressing a fusion protein comprising the signal polypeptide of claim 1 and a heterologous protein, and
(b) recovering the heterologous protein.